StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) stock

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$5.70−0.81 (-12.44%)

Close on Nov 17, 2026Market cap $11.10MP/E –Yield –

Akari Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Akari Therapeutics's ebitda for the twelve months ending Dec 31, 2024 was -$21.63M. For fiscal 2024 it was -$21.63M. The highest annual figure on record is -$1.91M in fiscal 2014.

Annual ebitda

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$21.63M–
FY2023Dec 31, 2023-$16.80M–
FY2022Dec 31, 2022-$23.08M–
FY2021Dec 31, 2021-$17.21M–
FY2020Dec 31, 2020-$17.97M–
FY2019Dec 31, 2019-$16.94M–
FY2018Dec 31, 2018-$20.75M–
FY2017Dec 31, 2017-$37.74M–
FY2016Dec 31, 2016-$27.21M–
FY2015Dec 31, 2015-$30.57M–
FY2014Dec 31, 2014-$1.91M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$5.28M–
Q3 FY2024Sep 30, 2024-$2.93M–
Q2 FY2024Jun 30, 2024-$7.45M–
Q1 FY2024Mar 31, 2024-$5.98M–
Q4 FY2023Dec 31, 2023-$5.09M–
Q3 FY2023Sep 30, 2023-$2.51M–
Q2 FY2023Jun 30, 2023-$4.61M–
Q1 FY2023Mar 31, 2023-$4.59M–
Q4 FY2020Dec 31, 2020-$6.89M–
Q3 FY2020Sep 30, 2020-$245.90K–
Q2 FY2020Jun 30, 2020-$5.91M–
Q1 FY2020Mar 31, 2020-$4.92M-28187.0%
Q4 FY2019Dec 31, 2019-$7.82M–
Q3 FY2019Sep 30, 2019-$3.11M–
Q2 FY2019Jun 30, 2019-$6.03M–
Q1 FY2019Mar 31, 2019$17.53K–

More Akari Therapeutics figures

See a number that looks wrong?